Tenofovir (all routes except local)

Bone fractures / bone mineralisation anomalies

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S5122
R13292		 Gibb, 2012 Bone fractures throughout pregnancy prospective cohort exposed to other treatment, sick Adjustment: No Control group: zidovudine/lamivudine-based Exposed group: TDF/zidovudine/lamivudine Indication: HIV 0.56 [0.01;28.40] C 0/111   0/62 0 111
ref
Total 1 studies 0.56 [0.01;28.40] 0 111
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Gibb, 2012Gibb, 2012 0.56[0.01; 28.40]01110%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA0.22.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0.56[0.01; 28.40]-111 -NAGibb, 2012 1 case control studiescase control studies 0 Type of controls exposed to other treatment, sickexposed to other treatment, sick 0.56[0.01; 28.40]-111 -NAGibb, 2012 1 Tags Adjustment   - No  - No 0.56[0.01; 28.40]-111 -NAGibb, 2012 1 Control group   - zidovudine/lamivudine-based  - zidovudine/lamivudine-based 0.56[0.01; 28.40]-111 -NAGibb, 2012 1 Exposed group   - TDF/zidovudine/lamivudine  - TDF/zidovudine/lamivudine 0.56[0.01; 28.40]-111 -NAGibb, 2012 1 Indication   - HIV  - HIV 0.56[0.01; 28.40]-111 -NAGibb, 2012 1 All studiesAll studies 0.56[0.01; 28.40]-111 -NAGibb, 2012 10.210.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls exposed to other treatment, sick controlsexposed to other treatment, sick controls 0.56[0.01; 28.40]-111 -NAGibb, 2012 10.510.01.0